Abstract
The acceptance rate in the ICNJ was 46% (rejection rate: 54%) in 2022 and the average peer review time was around three weeks. Overall, 32 papers, including 16 (50%) original articles, 8 (25%) case reports, 6 (18.75%) review articles, and 2 (6.25%) letters to the Editor were published in 2022. The most published topics in 2022 were COVID-19 (6 papers), mental health, and cancers. Most publications focused on COVID-19, as a common topic worldwide. Some of the articles were published as editorial letters.1,2 There were papers about COVID-19 and mental health1 and COVID-19 and headache.2Six review papers were about “Upper Extremity Function After Stroke”, “Neurological Complications of COVID-19”, “Neuropathic Pain”, “Public Acceptance of the COVID-19 Vaccination”, “Consciousness in Sleep” and Molecular and Cellular Basis in Neurodegenerative Diseases”.3-8 Moreover, ICNJ presents eight rare, complex and challenging neurological and neurosurgical cases (“Fahr Syndrome and Syncope”, “Acute Hemifacial by Haemorrhagic Schwannoma”, “Multilevel Lumbar Spondylolisthesis”, “Convulsion Presentation of Parietal Meningioma”, “Coil Embolization in Pseudoaneurysm of the Supraglenoid Internal Carotid Artery”, “Physical Therapy for Erectile Dysfunction and Sensation”, “Traumatic Unilateral Basal Ganglia Haemorrhage”, and “Parenchymal Infarction After Subacute Subdural Hematoma Evacuation”).9-16 The editors and editorial board members of the journal believe that the publication of these cases can help develop good hypotheses for further studies in the future.Sixteen published original articles present new and novel assessments, diagnostic methods, prevention, treatment, and approaches of neurological disease, and valuable epidemiological features and findings to be used worldwide.17-32The International Clinical Neuroscience Journal is supported by Universal Scientific Education and Research Network (USERN). The goal of (ICNJ) is to continue publishing high quality and novel studies especially in areas of tissue engineering, molecular biology, personalized medicine, degenerative diseases and neuromodulation. We would like to invite all researchers from around the world to contribute to this journal. We appreciate the contributions of all the researchers and scientists who trusted the ICNJ.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
